Suhonen A S, Leppäluoto J, Salmi J
Acta Endocrinol (Copenh). 1984 Apr;105(4):482-6. doi: 10.1530/acta.0.1050482.
Urine samples from 8 healthy subjects, from 16 patients with primary hypothyroidism and 8 patients with Graves' hyperthyroidism were pre-purified in SP-Sephadex-C-25 cation-exchange-chromatography, subjected to reverse phase high-pressure liquid chromatography (HPLC) with 0.01 M ammonium acetate pH 4 as a polar and propanol as a non-polar solvent with a 1%/min gradient and assayed in our TRH radioimmunoassay. Urine TRH-immunoreactivity levels were measured before and after 3 months of treatment with thyroxine or methimazole. The urine TRH-levels in healthy subjects were 5.5 +/- 1.4 ng/1 (mean +/- SEM, n = 8). In the hypothyroid patients, the urine TRH levels were 50.6 +/- 40 ng/1 before and 71.7 +/- 45.3 ng/1 after 3 months of treatment with thyroxine. These values did not significantly differ from those in healthy subjects. The large variations were due to highly elevated values in 3 patients. In 2 hypothyroid patients with initially high urine TRH values, 67 and 657 ng/1, urine TRH was measured 5 and 18 months later and was found to have decreased to 5 and 11 ng/1. In the hyperthyroid patients, urine TRH levels were 10.3 +/- 3.9 ng/1 before and 8.9 +/- 3.3 ng/1 after the treatment with methimazole and did not differ significantly from the levels in healthy subjects. After 3 months of treatment, the hyper- and the hypothyroid patients were euthyroid. Our results show, that, except in 2 hypothyroid patients, there does not appear to be any relationship between urine TRH levels and serum TSH or thyroid hormone levels in hypothyroid and hyperthyroid patients.
从8名健康受试者、16名原发性甲状腺功能减退患者和8名格雷夫斯甲亢患者采集的尿液样本,先在SP - Sephadex - C - 25阳离子交换色谱中进行预纯化,然后采用反相高压液相色谱(HPLC),以0.01M pH 4的醋酸铵为极性溶剂、丙醇为非极性溶剂,以1%/分钟的梯度进行分析,并在我们的促甲状腺激素释放激素(TRH)放射免疫分析中进行检测。在使用甲状腺素或甲巯咪唑治疗3个月前后测量尿液TRH免疫反应水平。健康受试者的尿液TRH水平为5.5±1.4 ng/1(平均值±标准误,n = 8)。甲状腺功能减退患者在使用甲状腺素治疗3个月前尿液TRH水平为50.6±40 ng/1,治疗后为71.7±45.3 ng/1。这些值与健康受试者的值无显著差异。差异较大是由于3名患者的值极高。在2名最初尿液TRH值较高(分别为67和657 ng/1)的甲状腺功能减退患者中,5个月和18个月后测量尿液TRH,发现已降至5和11 ng/1。在甲亢患者中,使用甲巯咪唑治疗前尿液TRH水平为10.3±3.9 ng/1,治疗后为8.9±3.3 ng/1,与健康受试者的水平无显著差异。治疗3个月后,甲亢和甲减患者的甲状腺功能均恢复正常。我们的结果表明,除了2名甲状腺功能减退患者外,甲状腺功能减退和甲亢患者的尿液TRH水平与血清促甲状腺激素(TSH)或甲状腺激素水平之间似乎没有任何关系。